Thymic Epithelial Tumors: Clinical Outcomes and Treatment Strategies

Thymic epithelial tumours (TETs) encompass a spectrum of neoplasms arising in the anterior mediastinum, chiefly represented by thymomas and thymic carcinomas. Thymomas often present with indolent growth but harbour risks of local invasion and paraneoplastic autoimmunity, notably myasthenia gravis, whereas thymic carcinomas tend to exhibit aggressive behaviour, earlier metastasis and reduced five-year survival rates. The Masaoka–Koga staging system, integrating invasion and dissemination, remains central to prognostic assessment and treatment planning. Surgical resection is the cornerstone for localized disease, with complete excision correlating strongly with long-term survival. Adjuvant radiotherapy is considered for stage II–III thymomas and for completely resected thymic carcinomas, while advances in three-dimensional conformal and intensity-modulated techniques have improved local control with acceptable toxicity. Platinum-based chemotherapy, often anthracycline-containing for thymomas and cisplatin-preferred for carcinomas, yields response rates of approximately 40–70% in advanced cases. Immunotherapeutic approaches targeting PD-1/PD-L1 pathways have demonstrated antitumour activity but require careful management of immune-related adverse events. Emerging strategies include molecularly targeted agents guided by genomic aberrations and radiomics-driven imaging biomarkers to tailor multimodal therapy. This integrated paradigm underscores a shift towards precision management, combining surgical, radiation, systemic and diagnostic innovations to improve outcomes in this rare but clinically impactful group of mediastinal tumours.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Thymic Epithelial Tumors: Clinical Outcomes and Treatment Strategies publication trend

The graph below shows the total number of articles in thymic epithelial tumors: clinical outcomes and treatment strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Thymic epithelial tumours (TETs): Neoplasms arising from thymic epithelial cells, including thymomas and thymic carcinomas.

Thymoma: A generally indolent TET subtype characterised by epithelial cells intermixed with lymphocytes and associated with autoimmune phenomena.

Thymic carcinoma: A high-grade TET variant with pronounced invasiveness, early dissemination and poorer prognosis.

Radiomics: The extraction and analysis of quantitative features from medical imaging to characterise tumour phenotype and predict clinical outcomes.

Programmed death-ligand 1 (PD-L1): An immune checkpoint protein expressed on tumour or immune cells that can inhibit T cell activation when engaged.

Single-cell transcriptomics: A method to profile gene expression at the resolution of individual cells, revealing tumour heterogeneity and microenvironmental interactions.

References

1. Abnormal Cellular Populations Shape Thymic Epithelial Tumor Heterogeneity and Anti‐Tumor by Blocking Metabolic Interactions in Organoids. Advanced Science (2024).
2. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. Journal for ImmunoTherapy of Cancer (2019).
3. Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy. Journal of Cancer Research and Clinical Oncology (2014).
4. CT-Based Radiomics Signatures for Predicting the Risk Categorization of Thymic Epithelial Tumors. Frontiers in Oncology (2021).
5. Pan-Cancer Landscape Analysis Reveals Recurrent KMT2A-MAML2 Gene Fusion in Aggressive Histologic Subtypes of Thymoma.. JCO Precision Oncology (2020).